Depression and heart health (Credit: Canva)
Heart disease is often linked to high cholesterol, obesity, or lack of exercise. However, there is mounting evidence that suggests that mental health plays a crucial role in cardiovascular well-being. Stress, anxiety, and depression can silently strain the heart, increasing the risk of serious complications.
A recent study, published in Nature Human Behaviour, showed that loneliness has a significant impact on proteins present in a person's blood. For the study, researchers used data from more than 42,000 participants to explore whether the 9.3% who reported social isolation and 6.4% who reported loneliness had different levels of proteins in their blood compared with those who did not. The researchers then studied data that tracked the health of participants over an average 14-year period.
"We found around 90% of these proteins are linked to the risk of mortality," Dr Chun Shen, Fudan University in China, who is also the lead researcher said. "In addition, about 50% of the proteins were linked to cardiovascular disease, type 2 diabetes and stroke," he added.
Dr Shrey Kumar Srivastav, senior consultant at Sharda Hospital, said that subtle symptoms of heart disease, such as fatigue, shortness of breath, swelling in the lower legs, dizziness, and jaw pain, are often overlooked or attributed to stress and ageing. "Women, in particular, may experience atypical signs like extreme fatigue, indigestion, or upper abdominal pain instead of classic chest pain, leading to delayed diagnosis," he added.
Can Mental Health Issues Trigger Heart Diseases?
Chronic stress can trigger harmful cardiovascular effects, including elevated blood pressure, increased heart rate, and inflammation—key contributors to heart disease. Anxiety and depression further impact heart health by disrupting sleep patterns, raising stress hormone levels, and encouraging unhealthy habits like poor diet and inactivity.
Mental health issues like depression and anxiety have a profound impact on the heart. They don’t just affect emotions but can increase inflammation and put extra strain on the cardiovascular system, warns Dr Srivastav.
Certain risk factors, such as obesity and diabetes, disproportionately affect women, making them more vulnerable to heart failure with preserved ejection fraction (HFpEF). However, due to gender-specific symptom variations, heart disease in women often goes undiagnosed for longer.
Obesity is more prevalent in women than men and is a major risk factor for heart failure. Diabetes, too, has a greater impact on women’s heart health, yet diagnosis and treatment delays are common. Addressing this gap requires increasing awareness, training healthcare providers, and promoting early diagnostic tools,” explains Dr Srivastav.
How Can You Protect Your Heart?
A simple yet effective way to support heart health is by committing to a brisk 30-minute walk daily. Walking not only helps regulate blood pressure and manage weight but also improves circulation and reduces stress.
"Regular physical activity, paired with a heart-healthy diet rich in fruits, vegetables, whole grains, and lean proteins, significantly lowers cardiovascular risks," advises Dr Srivastav.
Heart disease can often go undetected until a major event occurs, making routine screenings essential.
- For women: Begin screenings around age 30 and continue with regular checkups.
- For men: Start screenings at age 35.
Health screenings, including blood pressure checks, cholesterol tests, and electrocardiograms (ECGs), are critical for early detection of silent heart conditions.
Credit: iStock
India has taken a significant step to strengthen the safety and authenticity of medicines by expanding its QR code-based drug traceability system.
The Ministry of Health and Family Welfare has amended the Drugs Rules, 1945, bringing additional categories of medicines—including vaccines, anti-cancer drugs and antimicrobials—under the Schedule H2 track-and-trace framework.
The move is aimed at enhancing supply chain transparency, curbing counterfeit medicines and enabling patients to verify key details about their medicines through a simple QR code scan.
In 2025, the government made it mandatory for the top 300 pharmaceutical companies to print or affix QR (Quick Response) codes on the packaging of the medicines they sell.
The new amendment significantly expands its coverage to include:
Also read: India Ends OTC Sale of Cough Syrups, Doctor's Prescription Now Mandatory
The amendment applies to all vaccines, antimicrobials, narcotic and psychotropic drugs covered under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985.
All anti-cancer drugs have also been included under Schedule H2 of the Drugs Rules, 1945.
According to the Health Ministry, manufacturers of these drug formulations will now be required to print or affix a Bar Code or Quick Response (QR) Code on the primary packaging label of the product or, where there is inadequate space, on the secondary packaging label.
The QR code shall store information that can be accessed through software applications to facilitate authentication and verification of the product throughout the supply chain.
The QR code will contain key product information, including:
Read More: Sleeping Too Little or Too Much? Neurologist Explains Health Risks
The enhanced traceability mechanism is aimed at facilitating authentication of medicines at various stages of the supply chain and enabling improved tracking and verification of drug products, the Ministry noted.
The measure is expected to strengthen regulatory oversight and support efforts to curb the distribution of spurious medicines in the market.
It will also contribute to the national fight against antimicrobial resistance (AMR) by enabling better identification and monitoring of counterfeit and substandard antimicrobial products.
Recognizing the need to provide adequate time to industry and other stakeholders for implementation, the Ministry has also prescribed phased timelines for compliance.
As per the Ministry, the provisions relating to vaccines, narcotic and psychotropic drugs, and anti-cancer medicines shall come into force from July 1, 2027.
The provisions relating to antimicrobials shall become effective from July 1, 2028.
The government's QR code move comes amid mounting concern over counterfeit and substandard medicines in the Indian market.
In May, the Central Drugs Laboratories identified 46 drug samples as Not of Standard Quality (NSQ), while State Drugs Testing Laboratories identified 113 drug samples as Not of Standard Quality (NSQ), according to the Health Ministry.
Further, one drug sample from Assam was identified as a spurious drug. It was manufactured by unauthorized manufacturers using a brand name owned by another company. The matter is under investigation and action will be taken as per the Act and Rules.
Credit: AI generated image
After a hantavirus outbreak aboard the luxury cruise ship MV Hondius sparked global concern in May, the World Health Organization (WHO) said its outbreak response is expected to conclude on July 2 if no additional cases are reported.
The WHO had recommended active health monitoring for all evacuated passengers for 42 days from their last exposure date, either in designated quarantine facilities or at home. The monitoring period ended on June 21.
The rat-borne virus outbreak claimed three lives and infected 13 people. It was caused by the Andes strain of hantavirus, which carries a risk of human-to-human transmission. There is currently no specific antiviral treatment or vaccine for the virus.
The Dutch-flagged ship departed from Ushuaia, Argentina, on April 1, visiting remote islands in the South Atlantic Ocean, including Tristan da Cunha, before heading to Tenerife in Spain's Canary Islands, where the remaining passengers were evacuated.
Also read: Immunotherapy Shows Early Promise Against Severe Hantavirus Lung Disease: Study
In a post on social media platform X, WHO Director-General Tedros Adhanom Ghebreyesus said that more than 650 contacts were identified and monitored by health authorities across 33 countries and territories.
"All but 54 contacts have completed their period of quarantine, and the remaining contacts are scheduled to complete their quarantine period by July 2," he told a press conference at WHO headquarters in Geneva.
"If no further cases are reported by then, WHO will consider the outbreak to be over," he added.
The WHO chief noted that the WHO would continue efforts to better understand both the outbreak and the virus.
The UN health agency is working with partners who collected environmental samples from the ship and is coordinating a study among those exposed to better understand how the disease develops.
"We are also working on having a sample of the virus shared with the WHO BioHub in Switzerland," he said.
"This will be important for developing diagnostics, therapeutics, and vaccines for future outbreaks."
Read More: Can Hantavirus Spread Through Semen And Breast Milk? What Experts Say
Meanwhile, the US Centers for Disease Control and Prevention (CDC), which officially ended its hantavirus outbreak response on June 24, said none of the 18 Americans who were aboard the cruise ship became ill during the outbreak or the subsequent 42-day incubation period.
“The successful conclusion of this response demonstrates the strength of a coordinated response to infectious disease threats that occur outside of our borders,” said CDC Acting Director Jay Bhattacharya in a statement.
“I am grateful for the world-class team at CDC, whose dedication and swift action helped identify potential exposures, provide clear guidance, and protect the American people. As a result, we prevented any new cases from arising in the US."
According to the WHO, hantaviruses are zoonotic viruses that naturally infect rodents and are occasionally transmitted to humans.
Globally, an estimated 100,000 to 200,000 hantavirus infections occur each year, with the majority reported in Asia, particularly China. Most cases are sporadic or occur in small clusters linked to contact with infected rodents.
In humans, hantavirus infection can cause severe disease and may be fatal, although the clinical presentation varies depending on the virus strain and geographic region.
Credit: AP
GLP-1 weight-loss drugs have taken the world by storm. One new entrant is Eli Lilly's retatrutide, which has demonstrated bariatric surgery-level weight loss.
Retatrutide is not yet FDA-approved or commercially available; it is expected to be available by the end of 2026.
According to a media report, Eli Lilly and the Food and Drug Administration (FDA) have allowed one person to gain access to the drug through the company's "compassionate use" program. It is generally used by patients with serious and immediately life-threatening medical issues to get access to experimental treatments.
STAT News, citing sources, reported that a request for drug access was made in April for a 79-year-old, well-connected man, and indicated that the person could be US President Donald Trump, who turned 80 a week ago.
The White House has aggressively denied the claim.
"This application was not for the President," said, White House spokesperson Kush Desai, while blasting STAT on X..
STAT claimed that "during the Covid-19 pandemic, Trump was notably one of the first people administered an antibody treatment from Regeneron after he contracted the virus, via this same compassionate use pathway".
Further, the media outlet cited that Ranganath Muniyappa, a senior clinician at the National Institutes of Health, had requested the drug to treat a patient for refractory obesity with obstructive sleep apnea and pulmonary hypertension, noting it inquired whether Trump has those conditions.
In response, Desai referred to a White House memo on Trump's most recent medical evaluation that did not contain any mention of obstructive sleep apnea or pulmonary hypertension.
Also read: President Donald Trump Remains In Excellent Health, Says White House
Earlier this year, Trump told The New York Times that he had not taken GLP-1 drugs like Wegovy and Ozempic but said, "I probably should."
Notably, Trump's latest physical exam revealed the president weighed 238 pounds, a 14-pound increase from April 2025 that nearly reached the threshold of clinical obesity.
Trump's health has been under increased scrutiny as he turned 80 this year and has been frequently seen with swollen ankles and bruises on his hands.
Read More: US FDA Panel Recommends First-Ever mRNA Flu Shot For Older Adults: All About The Moderna Vaccine
Retatrutide is similar to drugs like Zepbound and Wegovy that mimic the GLP-1 hormone. The drug aims to maximize weight-loss results with fewer side effects for users. If approved, it could be helpful for patients who are struggling to lose weight on the current versions of GLP-1 drugs.
Unlike Zepbound, which is a double agonist, retatrutide, mimics glucagon along with GLP-1. It thus, works like a triple agonist.
In the third phase of clinical trial, the drug helped people lose up to 30 per cent of their body weight, which is about 85 pounds. The results are on a par with bariatric surgery, which helps people shed approximately 25 to 35 per cent of their total body weight within one to two years. Doctors say that this is the largest weight loss ever witnessed in a medical trial.
Dr Shauna Levy, medical director of the Tulane Weight Loss Center, explained that the current GLP-1s are not good enough to induce weight loss in people dealing with severe obesity and those who have a BMI of 35. Bariatric surgery can provide the same, but it seems that Retatrutide will be far more effective for people living with a high BMI who are trying to achieve a healthy weight.
© 2024 Bennett, Coleman & Company Limited